-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
AMD 3465
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/185991-24-6.gif)
| Category | Human immunodeficiency Virus (HIV) |
| CAS | 185991-24-6 |
| Description | AMD 3465,a N-pyridinylmethylene monocyclam, is a selective antagonist of CXCL12/CXCR4-mediated interactions including ligand binding and receptor activation. With its enhanced potency against the CXCR4 receptor compared with plerixafor, AMD 3465 has been |
Product Information
| Synonyms | N-(pyridin-2-ylmethyl)-1-[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methanamine;hexahydrobromideAMD 3465 hexahydrobromide185991-07-5185991-24-6AMD3465 6 HBrC24H38N6.6BrHAMD3465; AMD 3465; AMD-3465GENZ-644494 N-(1,4,8,11- tetraazacyclotetradecanyl-1,4-phenylen |
| Molecular Weight | 410.60 |
| Molecular Formula | C24H38N6 |
| Canonical SMILES | C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CNCC3=CC=CC=N3.Br.Br.Br.Br.Br.Br |
| InChI | 1S/C24H38N6.6BrH/c1-2-13-29-24(5-1)20-28-19-22-6-8-23(9-7-22)21-30-17-4-12-26-15-14-25-10-3-11-27-16-18-30;;;;;;/h1-2,5-9,13,25-28H,3-4,10-12,14-21H2;6*1H |
| InChIKey | ARHBIBDGWDRBJH-UHFFFAOYSA-N |
| Boiling Point | 571.3±50.0 °C | Condition: Press: 760 Torr |
| Melting Point | 200-205 °C (decomp) |
| Flash Point | 299.3±30.1 °C |
| Purity | ≥98% |
| Density | 1.022±0.06 g/cm3 |
| Solubility | Soluble to 93.2 mg/ml in water, and to 34.0 mg/ml in DMSO |
| Appearance | Light-pink solid |
| Shelf Life | 2 years |
| Storage | Store in a cool and dry place and at 0 - 4°C for short term (days to weeks) or -73°C for long term (months to years). |
| Animal Admin | Two weeks after tumor cell implantation, cohorts of mice with approximately equivalent tumor bioluminescence are divided into equal control and treatment groups. Animals in AMD 3465 experiments receive s.c. osmotic pumps loaded with 10 mg/mL AMD 3465 in sterile PBS or PBS alone. Mice are imaged at least twice after implantation of cells to identify those with equivalent tumor growth rates. |
| Complexity | 413 |
| Exact Mass | 410.315796 |
| Index Of Refraction | 1.533 |
| In Vitro | AMD 3465 is a potent antagonist of CXCR4, inhibits binding of 12G5 mAb and CXCL12AF647 to CXCR4, with IC50s of 0.75 nM and 18 nM in SupT1 cells. AMD 3465 also potently inhibits the replication of X4 HIV strains (IC50: 1-10 nM), but has no effect on CCR5-using (R5) viruses. AMD3465 is cytotoxic to the X4 HIV-1 strains IIIB, NL4.3, RF and HE with an IC50 ranging from 6 to 12 nM. The IC50 for suppression of the HIV-2 strains ROD and EHO is 12.3 nM. AMD 3465 inhibits CXCL-12-induced growth in U87 and Daoy cells. AMD 3465 treatment stimulates the phosphorylation of Erk1/2 in U87 and Daoy cells. |
| In Vivo | AMD 3465 (2.5 mg/kg/d, s.c. for 5 weeks) significantly blocks the growth of U87 GBM and Daoy xenografts. |
| Target | CXCR; HIV |
| Vapor Pressure | 0.0±1.6 mmHg at 25°C |
| XLogP3-AA | 0.8 |
